Abstract
Objective:
Management of complex hard-to-heal (chronic) wounds presents a substantial challenge in various healthcare settings where logistical constraints and patient-related factors can impede wound closure. This retrospective study evaluates outcomes associated with the use of a dehydrated, full-thickness placental allograft (CompleteFT; ExtremityCare, LLC, US) composed of the amnion, chorion and intermediate layers, when applied to complex hard-to-heal wounds in a mobile care environment.
Method:
A retrospective analysis reviewed data collected between February 2024 and July 2025 from patients (aged ≥18 years) with complex hard-to-heal wounds. Data were retrieved from a single mobile wound care service provider team (Compassionate Care Concierge, US). Prior to allograft application, all wounds exhibited stalled healing for at least 30 days with standard of care (SoC). The allograft was applied to all wounds as an adjunct to SoC. Trend changes in wound surface area and percentage area reduction (PAR)across various wound aetiologies were assessed, with additional endpoints including the number of allograft applications and relevant patient parameters.
Results:
The patient cohort (n=114, with a total of 184 hard-to-heal wounds), included 51 males and 63 females, with a mean age of 73.1 years. Analysis revealed statistically significant PAR values for various wound aetiologies, such that: p<0.0001 for diabetic foot ulcers (n=11); venous leg ulcers (n=48); pressure ulcers (n=73); and wounds classified as ‘other’ (n=39). Surgical wounds (n=13) demonstrated a p<0.0007. The study allograft was well-tolerated, with no adverse events directly attributable to the product.
Conclusion:
Application of the full-thickness allograft as an adjunct to SoC presents a promising option for supporting wound size regression in complex, hard-to-heal wounds.
The global burden of complex, hard-to-heal (chronic) wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs) and pressure ulcers (PUs), presents a significant challenge to healthcare systems.1 Complex, hard-to-heal wounds are defined by a failure to predictably proceed through the established phases of physiological healing, classically arresting in a state of prolonged inflammation.2 The challenges of hard-to-heal wounds are multifactorial, stemming from a combination of local wound considerations (e.g., infection, ischaemia, and repeated pressure) and patient comorbidities (e.g., high body mass index, diabetes and vascular disease).2 Increasingly, hard-to-heal wounds are being recognised as a mortal disease associated with grave end-results on a scale similar to those observed for certain cancers.3 For example, scientific literature indicates that the five-year mortality rate associated with patients with DFUs and ischaemic ulcers exceeds the rate observed with common malignancies, including prostate and breast cancer.3,4 Additionally, when considering the mortality associated with hard-to-heal wounds, it should be recognised that the five-year mortality rate for patients who undergo diabetes-related limb amputations is approximately 50%.5 Collectively, these concerns underscore the need to recognise hard-to-heal wound repair as a significant burden which necessitates early management.
Effective early management requires a comprehensive and multifaceted approach that adequately addresses all underlying impediments to wound closure.2 Standard of care (SoC), which typically includes debridement, moisture balance and offloading, is foundational but often presents as insufficient for achieving closure.2 This has catalysed the development and adoption of adjunct/supporting solutions including tissue-based products, such as placental tissue allografts.
Published literature has shown that the placenta provides a native extracellular matrix (ECM) scaffold that supports cellular migration and proliferation; delivers cytokines that promote angiogenesis and granulation; and exerts anti-inflammatory, anti-fibrotic, and immunomodulatory effects that may help facilitate transition of the wound from a hard-to-heal to a healing state.6,7 Cellular, acellular and matrix-like products (CAMPs), including placental-derived allografts, are now widely used in wound care settings as a physical wound covering.7,8,9 These membranes are often processed using proprietary or unique methods, resulting in a wide variety of available single- and multilayer constructs.6,7
Placental allografts that retain the amnion, chorion and intermediate spongy layers are considered full-thickness allografts. In these allografts, the amnion provides a basement membrane rich in collagens and laminin, the chorion offers a scaffold, and the intermediate layer consists of a non-fibrillar meshwork that connects the two.6,10 Preserving this tripartite architecture is hypothesised to provide a more mechanically robust scaffold and a more complete biological payload compared to single-layer grafts.8,11,12,13,14 Moreover, a previous study reported favourable outcomes associated with such full-thickness allografts.11
The present analysis was undertaken to improve understanding of this characterisation, through examining clinical outcomes observed in a larger, heterogenous cohort of patients receiving full-thickness allograft applications during their overall course of care. In addition to understanding the changes observed in wound size reduction via surface area (SA) and percentage area reduction (PAR) trends, further outcomes tracked included the incidence of adverse events (AEs) associated with use of the allograft and number of allograft applications.
Methods
Ethical approval and patient consent
This study was a retrospective cohort analysis of patient data collected from the electronic health records (EHR) of a mobile wound care provider servicing multiple locations in and around Denver, Colorado, US. Records were collected for patients with documented application of the allograft. The collection and evaluation of all protected patient health information was performed in a Health Insurance Portability and Accountability Act-compliant manner, and all patient data were fully deidentified to ensure patient confidentiality and privacy.
The study was reviewed and approved by Advarra Institutional Review Board (IRB). Using the [US] Department of Health and Human Services regulations 45 (Code of Federal Regulations) CFR 46.104(d)(4), the IRB determined that this study is exempt from IRB oversight. Research was conducted in full accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Declaration of Helsinki as amended in 2013.
General written informed patient consent (encompassing the use of data and images) was obtained at the start of care by the patient provider team.
Product compliance
The study allograft (CompleteFT; ExtremityCare, LLC, US) is a dehydrated, terminally sterilised, full-thickness placental tissue allograft that contains the amnion, chorion and intermediate (spongy) layer of the placenta. The product meets all criteria to be compliant with Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P) that are regulated by the US Food and Drug Administration (FDA) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.
Patient eligibility and data collection
Patients who received the study allograft applications between February 2024 and July 2025 from a single mobile wound care service provider team were included in the study. Patients were identified through a query of the EHR database of the service provider, Compassionate Concierge Physicians, US. Inclusion criteria for the study were as follows:
•
Patients aged ≥18 years
•
Presence of a medically diagnosed complex, hard-to-heal wound
•
Wound duration of at least four weeks prior to the first application of the allograft
•
Documented failure to demonstrate signs of wound closure (per wound care regulations)
•
There were no adjunct use of allografts other than the study allograft during the course of application.
Patient profile data were extracted from the provider group’s EHR system. These included: demographic data (e.g., age, biological sex, race); smoking status; mobility classifications; diabetes diagnosis; and wound characterisation information. The latter encompassed: wound aetiology (e.g., VLU, DFU, PU, surgical, trauma, etc.); anatomical location; wound duration; and temporal wound measurements (including length, width and depth).
Wound assessment
Wound assessments were performed and recorded by the treating provider(s) at the initial care visit (prior to first allograft application) and at each subsequent visit. Wound dimensions were measured using a sterile, single-use ruler. Overall wound surface area was calculated as length×width when the ruler was positioned externally over the wound. Depth was measured by carefully inserting a sterile, cotton-tipped applicator into the wound, at its deepest point, after which the applicator was placed by a ruler to notate the value. Wound measurements were meticulously documented on standardised forms per application visit to ensure appropriate adherence to wound care and allograft use. Where applicable, the wound was also digitally assessed via a wound imaging device to verify size and bacterial bioburden.
Statistical analysis
Data were analysed via SAS Institute Inc., US, (Version 9.4). Descriptive statistics were used to summarise patient characteristics and outcomes, whereas categorical variables are presented as counts and percentages. Where possible, interquartile ranges are portrayed to illustrate the spread of the data, and to provide understanding of variability given the inherent heterogeneity within patient populations and wound aetiologies. The Wilcoxon signed-rank test was performed using the null hypothesis of no change from baseline to provide a clinically relevant comparator point for evaluating wound size changes as statistically significant. A p-value of ≤0.05 was deemed statistically significant.
Allograft application procedure Wound site preparation
Prior to commencing allograft application procedures, patient documentation and history were comprehensively reviewed to confirm medical necessity. Additionally, appropriate insurance and consent details were also obtained and verified as needed. The application of the allograft was completed by trained wound care providers during mobile, in-home visits. At each visit, the wound was prepared according to standard clinical practice, following a sequence of steps grounded in best practice for wound bed preparation and allograft application. This included cleaning the wound site based on wound type, wound characteristics and patient needs. Duration of debridement and wound site cleaning could vary depending on wound type, severity and extent of necrotic tissue, as well as other site-specific or patient-specific factors. Typically, wounds were debrided for approximately 15 minutes by soaking with Vashe solution (Urgo Medical North America, US). Surrounding tissue and wound bed were scrubbed and cleansed with gauze soaked in Vashe solution to remove devitalised tissue.
Allograft application
The most appropriate size of allograft was selected to minimise wastage. The allograft was hydrated with sterile saline before it was applied directly to the prepared wound bed. It was positioned meticulously to ensure maximal coverage of the entire wound. The allograft was then secured in place with a non-adherent primary contact layer, followed by secondary dressing at the discretion of the provider. This composite dressing system was used to protect the allograft, control exudate and provide a conducive wound closure environment for the wound and the surrounding area. Weekly wound care and allograft applications were preformed based on the provider’s assessment of wound progress.
Results
Patient and wound demographics
A total of 114 patients (51 male, 63 female) with 184 distinct hard-to-heal wounds met the retrospective assessment criteria and were included in the final analysis. The baseline patient characteristics are summarised in Table 1, whereas, wound type categorisations are detailed in Table 2. For the purposes of this study, wounds were categorised as: DFU (n=11); VLU (n=48); PU (n=73); surgical (n=13); and ‘other’ (n=39). ‘Other’ wounds included 10 wound subtypes (shown in Table 2), illustrating the heterogenous nature of the studied cohort. No AEs specific to the application of the placental allograft were observed within the patient records reviewed for this retrospective series.
Table 1. Patient demographics and baseline clinical characteristics (n=114)
| Characteristics | n | % |
|---|---|---|
| Age, years, mean±standard deviation | 73.11±11.83 | — |
| Race | ||
| White | 47 | 41.2 |
| American Indian or Alaskan Native | 2 | 1.8 |
| Other/mixed/unknown | 65 | 57.0 |
| Sex | ||
| Male | 51 | 44.7 |
| Female | 63 | 55.3 |
| Diabetes history | ||
| Yes | 52 | 45.6 |
| No | 32 | 28.1 |
| Not reported | 30 | 26.3 |
| Smoking history | ||
| Non-smoker/no history | 77 | 67.5 |
| Previous history | 17 | 14.9 |
| Current | 16 | 14.0 |
| Other (vaping/chewing tobacco) | 3 | 2.6 |
| Not reported | 1 | 0.9 |
| Ambulatory status | ||
| Assistive device/aid needed | 86 | 75.4 |
| Limited but mobile | 13 | 11.4 |
| Mobile | 15 | 13.2 |
Table 2. Baseline wound type categorisation (n=184)
| Wound type | n | % |
|---|---|---|
| Venous leg ulcer | 48 | 26.1 |
| Diabetic foot ulcer | 11 | 6.0 |
| Pressure ulcer | 73 | 39.7 |
| Surgical | 13 | 7.1 |
| Other* | 39 | 21.2 |
*Includes: trauma; wounds secondary to calcinosis cutis; arteriovenous malformations; non-pressure hard-to-heal; abrasion; dehisced; laceration; vasculitis; arterial; stiff person syndrome
Wound outcomes – percent area reduction (PAR)
PAR outcomes stratified by wound aetiology are presented in Table 3 along with their associated p-values. The Wilcoxon signed-rank test was used to evaluate whether the wound size change differed significantly from the null condition of no change from baseline. PAR was calculated as ((Initial SA – Final SA]/Initial SA) × 100, where SA is the surface area which was obtained using length and width measurements initially captured by the providers at the time of visit. Initial SA is the baseline measurement attained prior to allograft application, whereas Final SA is the measurement taken after final application of the allograft.
Table 3. Percentage area reduction (PAR) outcomes stratified by wound aetiology
| DFU | VLU | PU | Surgical | Other | |
|---|---|---|---|---|---|
| n | 11 | 48 | 73 | 13 | 39 |
| Mean PAR* | 69.2 | 80.9 | –157.9 | 70.1 | 46.1 |
| Median PAR | 75.8 | 98.1 | 82.8 | 98.3 | 78.3 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0007 | <0.0001 |
*The observed mean, particularly the negative values, was influenced by a small number of outliers, which were retained for this table and statistical summary. For this reason, the median PAR values present a more robust measure of central tendency, as they are less affected by the extremes. DFU—diabetic foot ulcer; PU—pressure ulcer; VLU—venous leg ulcer
Wilcoxon signed-rank test revealed statistically significant p-values for PAR outcomes based upon wound aetiology, with a p-value of <0.0007 for surgical wounds and a p-value of <0.0001 for DFUs, VLUs, PUs and ‘other’ wounds (Table 3). The frequency of PAR is depicted in Fig 1. Within each wound type, the majority of the patient population achieved a PAR of ≥70% by the time the final allograft was applied. Of the 11 patients with DFUs, 54.5% (n=6) had a PAR of ≥70% and of the 48 patients with a VLU, 81.3% (n=39) fell into the high PAR ranges. This trend was consistent across PUs (64.4%; n=47), surgical wounds (69.2%; n=9), and ‘other’ wounds (59.0%; n=23). In each wound category, <15% of the patient population exhibited a negative PAR, indicating that increases in wound dimensions and poor response to allograft applications were minimal. The low incidence of negative PAR supports a favourable overall application effect for the study allograft across varying aetiologies.

Fig 1. Percentage area reduction (PAR) frequency by wound type. DFU—diabetic foot ulcer; PU—pressure ulcer; VLU—venous leg ulcer
Additionally, the box-and-whisker plots shown in Fig 2 demonstrate high central tendency values for both the DFU (median: 75.8) and VLU (median: 98.1) cohorts, regardless of the expected heterogeneity across patients, providing a reliable picture of how each wound type behaved when the study allograft was applied as an adjunct to SoC in the real-world, mobile wound care setting. Fig 3 depicts the PAR outcomes for all other wounds included in the study. The primary difference between Fig 3a and 3b is that 3a excludes one patient with a PU (n=72). The patient’s extreme PAR obscured visualisation of the broader data distribution trends, therefore the patient case was excluded in Fig 3a for added data transparency and to facilitate clearer depiction of the trends to understand observed impacts of allograft applications. The overall retention of the central tendency values between Fig 3a and 3b shows that each of the wound aetiologies observed a PAR of >75%. To note, the outlier did not experience an AE related to the allograft application.


Fig 4 provides representative patient images at sequential timepoints (prior to initial allograft application, immediately prior to final application, and one week post final application), highlighting examples of wound progression which supplement the qualitative outcomes described above.

Wound outcomes – surface area reduction (SAR)
SA outcomes stratified by wound aetiology are presented in Table 4. Mean and median values are presented to demonstrate the overall trend towards wound size reduction. The table summarises data obtained prior to allograft application as compared to data obtained post allograft application. The difference between the two assessment timepoints consistently favours a reduction in wound SA, underscoring the net change trend of wound size regression across the different wound aetiologies.
Table 4. Mean, median and net change in surface area reduction, stratified by wound aetiology
| Pre-allograft cm2 | Postallograft, cm2 | Net change trend | Net change, cm2 | |
|---|---|---|---|---|
| Diabetic foot ulcer, n=11 | ||||
| Mean | 19.4 | 8.2 | ↓ | 11.2 |
| Median | 17.7 | 1.0 | ↓ | 16.7 |
| Venous leg ulcer, n=48 | ||||
| Mean | 24.6 | 3.8 | ↓ | 20.8 |
| Median | 8.5 | 0.2 | ↓ | 8.3 |
| Pressure ulcer, n=73 | ||||
| Mean | 9.0 | 5.9 | ↓ | 3.1 |
| Median | 5.5 | 0.3 | ↓ | 5.2 |
| Surgical, n=13 | ||||
| Mean | 136.5 | 107.5 | ↓ | 29.0 |
| Median | 7.9 | 0.0 | ↓ | 7.9 |
| Other, n=39 | ||||
| Mean | 14.4 | 13.1 | ↓ | 1.3 |
| Median | 7.5 | 0.5 | ↓ | 7.0 |
Wound outcomes – number of allograft applications
Table 5 depicts that 31.5% of the wounds in this retrospective analysis received 1–5 applications, while 68.5% received 6–10 applications. When assessing PAR values based on the number of allograft applications stratified per wound aetiology (Table 6), it can be observed that wounds receiving 1–5 applications demonstrated relatively high PAR (median between 60.3–100.0%). Notably, for wounds requiring 6–10 placental allograft applications, the median PAR ranged between 71.4–98.3%. The comprehensive cumulative PAR ranged from 60.3–100.0% across varying allograft application counts. Overall, the favourable percentages suggest that application of the allografts supported positive wound size reduction trajectories across varying wound types.
Table 5. Number of allograft applications stratified by wound aetiology
| DFU (n=11) | VLU (n=48) | PU (n=73) | Surgical (n=13) | Other (n=39) | Totals (n=184) | |
|---|---|---|---|---|---|---|
| Median count | 7 | 10 | 6 | 6 | 10 | — |
| Categorical, n (%) | ||||||
| 1–5 applications | 5 (45.0) | 8 (17.0) | 29 (39.7) | 6 (46.2) | 10 (25.6) | 58 (31.5) |
| 6–10 applications | 6 (55.0) | 40 (83.0) | 44 (60.3) | 7 (53.8) | 29 (74.4) | 126 (68.5) |
DFU—diabetic foot ulcer; PU—pressure ulcer; VLU—venous leg ulcer
Table 6. Median percentage area reduction (PAR) values by number of allograft applications and wound aetiology
| DFU (n=11) | VLU (n=48) | PU (n=73) | Surgical (n=13) | Other (n=39) | |
|---|---|---|---|---|---|
| 1–5 applications | |||||
| Wound count, n | 5 | 8 | 29 | 6 | 10 |
| PAR, median % | 68.0 | 100.0 | 91.5 | 60.3 | 100.0 |
| 6–10 applications | |||||
| Wound count, n | 6 | 40 | 44 | 7 | 29 |
| PAR, median % | 87.0 | 96.0 | 79.1 | 98.3 | 71.4 |
DFU—diabetic foot ulcer; PU—pressure ulcer; VLU—venous leg ulcer
Adverse effects and tolerability
The allograft applications were well tolerated across patients. There were no noted instances of AEs directly attributable to the placental allograft, such as allergic reaction, immune response or allograft rejection.
Discussion
The results of this retrospective analysis indicate that the adjunctive use of a full-thickness placental allograft was associated with positive wound regression trend outcomes in a patient population with complex/hard-to-heal wounds that had failed to respond to SoC alone. These findings are consistent with a growing body of evidence supporting the use of placental-derived tissues as wound coverings and suggest that this modality is a viable adjunct for supporting the process of addressing hard-to-heal wounds.
The observed benefit of including placental allografts during the care process is likely multifaceted, stemming from their preserved native structure. Unlike single-layer amniotic membranes, the inclusion of the chorion and intermediate spongy layer provides a more conducive environment due to the native composition of these layers, retaining the inherent, basic characteristics of the placental tissue.8,13 This is critically important, because hard-to-heal wounds are often stalled in a state of prolonged inflammation that is characterised by excessive levels of proteases and reactive oxygen species that degrade the native ECM, leading to cellular senescence and a failure to progress toward wound closure.7 The rich composition provided by the full-thickness study allograft contributes to its integrity and utility to serve as a strong wound barrier; likely helping modulate the wound environment, including retaining moisture, thereby supporting the body to naturally transition toward the proliferative phase.
To contextualise this performance, it is useful to compare these outcomes with those associated with prior published tissue technologies. One such technology—assessed as part of a pivotal, multicentre, 12-week clinical trial—is a bilayered living cellular construct consisting of a bovine collagen matrix seeded with living human neonatal fibroblasts and a neonatal keratinocyte neoepidermis.6,7,15,16,17,18 In this clinical trial, the construct showed a median time to wound closure of nine weeks, achieving what authors described as ‘complete healing’ in 56% of cases compared with 38% in the control group (p=0.0042). The study also portrayed that hard-to-heal DFUs in the allograft group reduced in size significantly faster than those wounds treated with SoC alone after an average of four applications (65 days versus 90 days, respectively; p=0.0026).15
While this current retrospective study does not incorporate all elements commonly seen in pivotal, prospective trials due to its retrospective nature, the findings nonetheless demonstrate favourable wound size regression trends. The results stratified per wound aetiology show positive outcomes with median PAR value ranging between 75.8–98.3%, with statistically meaningful p-values (ranging from p<0.0001 to p<0.0007) stressing clinical relevance. The results remain compelling even with a sample size of 11 DFUs (median PAR: 75.8%; p<0.0001) and 48 VLUs (median PAR: 98.1%; p<0.0001). Together, the findings highlight that the retrospective, real-world data effects measure up to the statistical expectations established from prior formalised clinical investigations.
Outcomes observed with other placental allografts
The findings from this study align with evidence from randomised controlled trials (RCTs) that have rigorously tested dehydrated amnion/chorion membranes to demonstrate the impact of placental allografts as adjuncts to SoC. DiDomenico et al.19 published data for an 80-patient RCT assessing DFUs in which they found 85% of wounds managed with a minimally processed dehydrated human amnion/chorion membrane achieved closure by 12 weeks, compared to only 33% of those receiving SoC. The mean time to wound closure was also significantly faster: 37 days for the allograft group versus 67 days for the SoC group.19
Similarly, a 109-patient VLU RCT by Bianchi et al.16 reported 60% of patients achieved wound closure at 12 weeks with weekly application of a dehydrated human amnion/chorion membrane, versus 35% with SoC alone; a Cox regression analysis revealed that patients who received the allograft were 2.26 times more likely to experience wound closure.
Additionally, a 218-patient DFU trial presented by Cazzell et al.17 demonstrated a 48% greater probability of wound closure using a dehydrated full-thickness allograft, achieving a median time to closure of 84 days, while wounds in the SoC group failed to close by the 12-week endpoint. The consistency of these positive results across multiple trials, differing hard-to-heal wound aetiologies, and various full-thickness allograft products reinforces the effect observed in this present heterogeneous, real-world patient cohort.
Location and patient heterogeneity
The findings of this study were generated in a mobile, in-home clinical setting, demonstrating that effective wound care can be delivered in diverse locations. The successful deployment of the study allograft as part of the care regimen in this versatile environment highlights the clinical utility and adaptability of placental tissue technologies across various clinical care settings. The results support the notion that the stability and ease of application features of such allografts are well-suited for a setting predisposed to varying logistical realities encountered during wound care.
Patient populations receiving mobile wound care, such as those in this study, are also often characterised by factors that impede the wound closure process, such as advanced age, limited mobility, behavioural considerations (such as patient adherence to wound care instructions), and complex comorbidities.20 While previous assessments of placental allografts for hard-to-heal wounds in patients with such comorbidities have been promising, the available evidence is sparse. For example, a 2018 case series assessing allograft use in older patients with multiple comorbidities (diabetes, obesity, polymyalgia rheumatica, lymphoedema, peripheral vascular disease, steroid use and neuropathy) reported that all patients achieved complete wound closure.21 The mean time to closure for the five wounds in the study was 4.8 weeks, with no complications, AEs, or wound recurrence reported.21
Other case series have likewise demonstrated positive outcomes using placental allografts as adjunct care modalities in highly complex cases including neuropathy, Charcot neuroarthropathy, hypertension, hyperlipidaemia, hypothyroidism, peripheral arterial disease, coronary artery disease, chronic kidney disease, chronic venous insufficiency, lymphoedema, chronic atrial fibrillation requiring anticoagulation, and chronic obstructive pulmonary disease.22,23 The present study contributes to this body of evidence by providing data on the use of products, such as placental allografts, in real-world, heterogenous patient populations.
Potential implications for patient care
The observations of this study support several emerging considerations in contemporary wound care science. The data adds to the growing scientific knowledge which suggests an opportunity to reframe current approaches in the care paradigm of hard-to-heal wounds by incorporating tissue technology adjunct measures earlier on. Importantly, there is an opportunity to provide clinically meaningful benefits, such as reduction in amputations, hospitalisations, and in overall healthcare utilisation—ideally leading to cost-saving prospects for patients across various geographies and population demographics. Understanding there is a critical need to reduce the incidence of amputations and other grave outcomes associated with hard-to-heal wounds, serious consideration should be given to adoption of such allograft solutions into best practices and guidelines. The successful outcomes observed across this study’s patient population exhibit the potential versatility and practical utility of placental allografts.
Limitations
As this study was conducted retrospectively, it provides valuable insight using real-world evidence derived and analysed using pre-existing data. Nonetheless, it is understood that prospective and randomised, controlled studies allow for more stringent standardisation and statistical power methodologies to be deployed. Given that analysis was constrained to using available patient data, this may also present survivorship bias. It is suggested that further multicentre studies with diverse patient demographics be conducted to further validate the shared results.
Conclusions
In this retrospective evaluation of complex hard-to-heal wounds managed in a mobile clinic setting, application of a full-thickness placental allograft as a wound barrier along with SoC found favourable wound closure trajectories, irrespective of wound aetiology. The observed results are consistent with the promising capabilities of placental allografts illustrated in other studies examining the potential role of such allografts in supporting wound care as adjuncts to SoC during the care of complex wounds. The data captures outcomes in the context of routine clinical practice, thereby alluding to the practical effectiveness of the placental allograft across heterogenous patient populations and mobile settings. These findings justify further investigation through additional large-scale retrospective and prospective trials, including RCTs.
Reflective questions
•
What are the most vital properties of placental-derived allografts that you believe contribute to wound closure?
•
Based on the current scientific literature and/or your clinical experiences, what patient populations benefit the most from placental allografts?
•
Given the learnings from this manuscript and other published literature, what clinical scenarios have you found most promising for application of placental tissue allografts?
Acknowledgements:
The authors would like to extend their gratitude to the entire team at Compassionate Concierge Physicians, US, who brought this work to fruition through their collective support and dedication.
Tissue was acquired for and processed by RegenTX Partners, LLC, US, an affiliate company of Tiger BioSciences. The product referenced within this manuscript, CompleteFT, is a trademark of Extremity Care, LLC. US.
The views expressed in the submitted article are of the author(s) and are not an official position of the organisation.